glaxo aims high after profit fall glaxosmithkline saw its profits fall last year to bn bn but europe s biggest drugmaker says a recovery during is on the way cheap copies of its drugs particularly anti depressants paxil and wellbutrin and a weak dollar had hit profits but global sales were up in the firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug chief executive jean pierre garnier said it had been a difficult year in early afternoon trade in london the company share price was down at pence mr garnier said the company had absorbed over bn of lost sales to generics but still managing to grow the business the continuing success of our key products means we can now look forward to a good performance in he said will also be an important year in terms of research and development pipeline progress however the firm discontinued development of an experimental treatment for obesity known as after disappointing clinical trial results glaxo is relying on new treatments for conditions such as cancer diabetes depression hiv aids and allergies to lift the pace of sales growth after several disappointing years